drugset / Trial / NCT00649155

Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg

NCT00649155

Phase 1 Completed 36 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's ciprofloxacin extended-release 500 mg tablets to Bayer's Cipro® XR 500 mg tablets following a single, oral 500 mg (1 x 500 mg) dose administered under fasting conditions.

Timeline

Start
2005-11
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciprofloxacin Small molecule 500 mg Oral

Indications

No indication recorded.